United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - olodaterol hydrochloride (unii: 65r445w3v9) (olodaterol - unii:vd2ysn1afd) - olodaterol 2.5 ug - striverdi respimat is a long-acting beta2 -agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. striverdi respimat is not indicated to treat acute deteriorations of copd [see warnings and precautions (5.2) ]. striverdi respimat is not indicated to treat asthma. the safety and effectiveness of striverdi respimat in asthma have not been established. use of a laba, including striverdi respimat, without an inhaled corticosteroid is contraindicated in patients with asthma [see warnings and precautions (5.1) ]. striverdi respimat is not indicated for the treatment of asthma. risk summary there are no adequate and well-controlled clinical studies with striverdi respimat in pregnant women to inform of drug-associated risk of adverse pregnancy-related outcomes. there are clinical considerations with the use of striverdi respimat in pregnant women [see clinica

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f), olodaterol hydrochloride (unii: 65r445w3v9) (olodaterol - unii:vd2ysn1afd) - tiotropium 3.124 ug - stiolto respimat is a combination of tiotropium and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use - stiolto respimat is not indicated to treat acute deteriorations of copd [see warnings and precautions (5.2)]. - stiolto respimat is not indicated to treat asthma. the safety and effectiveness of stiolto respimat in asthma have not been established. use of a laba, including stiolto respimat, without an inhaled corticosteroid is contraindicated in patients with asthma [see warnings and precautions (5.1)] . stiolto respimat is not indicated for the treatment of asthma. stiolto respimat is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product [see warnings and precautions (5.4)] . in clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, inc

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - olodaterol hydrochloride, quantity: 2.736 microgram/actuation (equivalent: olodaterol, qty 2.5 microgram/actuation); tiotropium bromide monohydrate, quantity: 3.124 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; benzalkonium chloride; hydrochloric acid; disodium edetate - spiolto respimat is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - olodaterol hydrochloride, quantity: 2.736 microgram/actuation (equivalent: olodaterol, qty 2.5 microgram/actuation); tiotropium bromide monohydrate, quantity: 3.124 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; benzalkonium chloride; hydrochloric acid; disodium edetate - spiolto respimat is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - olodaterol hydrochloride, quantity: 2.736 microgram/actuation (equivalent: olodaterol, qty 2.5 microgram/actuation); tiotropium bromide monohydrate, quantity: 3.124 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; benzalkonium chloride; hydrochloric acid; disodium edetate - yanimo respimat is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - olodaterol hydrochloride, quantity: 2.7 microgram/actuation (equivalent: olodaterol, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: disodium edetate; citric acid; purified water; benzalkonium chloride - striverdi respimat is a long-acting beta2-agonist indicated for once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - olodaterol - inhalation solution - 2.5 microgram(s) - olodaterol

Malta - English - Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - olodaterol, tiotropium bromide - inhalation vapour, solution - olodaterol 2.5 µg tiotropium bromide 2.5 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - olodaterol - pressurised inhalation, solution - olodaterol 2.5 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - olodaterol, tiotropium bromide - inhalation vapour, solution - olodaterol 2.5 µg tiotropium bromide 2.5 µg - drugs for obstructive airway diseases